Promoted Content
Promoted Content

Find Drugs for Genetic Disease in Phase II/ Phase III Clinical Development


All Data

Filters Filter refresh
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothSanofi Active Ingredient Solutions cover both APIs sales & CDMO.

            Contact the Supplier

            Lead Product(s): Olipudase alfa

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 30, 2020


            Olipudase alfa is the first and only investigational enzyme replacement therapy in late-stage development for the treatment of ASMD.